Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3′-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma

Cancer Science

Volumn 98, Issue 12, 2007, Pages 2002-2008

  Kawaguchi, Wakae ^a   Itamochi, Hiroaki ^a   Kigawa, Junzo ^a   Kanamori, Yasunobu ^a   Oishi, Tetsuro ^a   Shimada, Muneaki ^a   Sato, Sinya ^a   Shimogai, Ruri ^a   Sato, Seiya ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANNEXIN A5; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 35548931061     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00624.x     Document Type: Article

References (32)

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006; 20: 207-25.
2. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20: 1248-59.
3. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
4. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: 3 years results. J Nat Cancer Inst 2000; 92: 699-708.
5. Ahmedin J, Rebecca S, Elizabeth W et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
6. Du Bois A, Pfisterer J. Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer 2005; 15: 42-50.
7. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093-100.
8. Sunters A, Madureira PA, Pomeranz KM et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 2006; 66: 212-20.
9. Qiu LW, Jiang Q et al. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol 2005; 27: 1441-8.
10. Mabuchi S, Ohmichi M, Kimura A et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002; 277: 33490-500.
11. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-64.
12. Bellacosa A, de Feo D, Godwin AK et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64: 280-5.
13. Liu SQ, Yu JP, Yu HG, Lv P, Chen HL. Activation of Akt and ERK signaling pathways induced by etoposide confer chemoresistance in gastric cancer cells. Dig Liver Dis 2006; 38: 310-18.
14. Downward J. Cancer biology: Signatures guide drug choice. Nature 2006; 439: 274-5.
15. Powis G, Ihle N, Kirkpatrick DL. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 2006; 12: 2964-6.
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
17. Shtil AA, Mandlekar S, Yu R et al. Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene 1999; 18: 377-84.
18. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 2001; 60: 290-301.
19. McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-79.
20. 1/S transition. J Biol Chem 2004; 279: 43861-9.
21. Zecevic M, Catling AD, Eblen ST et al. Active MAP kinase in mitosis: localization at kinetochores and association with the motor protein CENP-E. J Cell Biol 1998; 142: 1547-58.
22. Reszka AA, Seger R, Diltz CD, Krebs EG, Fischer EH. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc Natl Acad Sci USA 1995; 92: 8881-5.
23. Brognard J, Dennis PA. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Deaths Differ 2002; 9: 893-904.
24. Hu Y, Bally M, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2003; 2: 641-9.
25. Mackeigan JP, Collins TS, Ting JPY. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275: 38953-6.
26. McDaid HM, Lopez-Barcons L, Grossman A et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005; 65: 2854-60.
27. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene 2003; 22: 7280-95.
28. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
29. Lee JT Jr, Steelman LS, McCubrey JA. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004; 64: 8397-404.
30. Del Bufalo D, Di Castro V, Biroccio A et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002; 61: 524-32.
31. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-92.
32. Sinha D, Bannergee S, Schwartz JH, Lieberthal W, Levine JS. Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis. J Biol Chem 2004; 279: 10962-72.